AIkido Pharma Inc.
Stock Promoter Performance
Last 1 Stock Promotions By "Broad Street Alerts"
|SPONF||SponsorsOne Inc.||March 8, 2021||0.045||0%|
AIKI Promotional Newsletter
The following is a newsletter released by "Broad Street Alerts" promoting AIkido Pharma Inc.
Phase 1 testing data will be presented at the 2021 ASCO Annual Meeting June 4, 2021
We can extrapolate the Phase 1 data to be presented will be a near-term catalyst in the next few weeks.
Good day everyone,
Aikido Pharma AIKI Has $100M in Cash, Where Might That Pile of Money Take Them
We are continuing our coverage of AIkido Pharma Inc. NASDAQ AIKI
Current price $1.07share
This morning, . Phase 1 testing data will be presented at the 2021 ASCO Annual Meeting June 4, 2021. The Phase I study is of the company product 225Ac-J591 for men with metastatic castration-resistant prostate cancer mCRPC.
Part of the presentation description states PSMA-targeted alpha-emitter 225Ac utilizing intact antibody J591 is tolerable with early evidence of clinical activity. Based upon these results, a follow up study NCT04506567 testing multiple and fractionated dosing of 225Ac-J591 is underway.
Moving into a next level clinical trial is a big development for any biopharma company and can act as a catalyst for the companys value. Biopharma companies are built on these kinds of milestones.
In February, AIKI raised $75M in a share offering, a move that built the $100M pile of cash they are sitting on. Those shares were sold at $1.60, considerably higher than todays price.
What could the next move be for a company valued at $95M with a cash position at $100M
AIKI could plow that cash into development of their pipeline. The addition of Dr. Matthew Frieman, a world-renowned virologist with expertise in coronaviruses to the AIKI Scientific Advisory Board last month indicates company interest in developing their anti-viral program. The news today indicates a move to a next level clinical trial.
AIKI could seek an acquisition that would either compliment the development of their current pipeline or bring products to add to it.
AIKI could be a party to a reverse merger. Many larger biopharma companies would likely salivate over a $100M pile of cash. A reverse merger, funded by an acquirers shares, could give another company access to all that cash. The question is, what value in shares would another company give up to get all that cash backing them
These scenarios are all conjecture, of course, yet all are possibilities. Suddenly, AIKI is being talked about in the biopharma circles. The consistent flow of company developments and the big cash position have created a real buzz about AIKI.
Stay tuned and stay informed,
Chart Setup, Momentum, Insider Buying and Recent Developments at AIkido Pharma AIKI
AIKI has a book and a cash value position that both exceed the companys market value.
Good day everyone,
Initiating coverage of AIkido Pharma Inc. NASDAQ AIKI, biotechnology development company, focused on small-molecule anti-cancer therapeutics and an antiviral platform.
Current price $1.06share
Outstanding est. 89.3M shares
Float est. 82.4M shares
52-week range $.47 to $2.55share
Cash per share est. $1.15 3-31-21
AIKI has no debt.
We noticed some new developments at AIKI and thought these potential catalysts could lead to a near term gain. We were not the only ones as the companys value increased 15% over Monday and Tuesdays sessions this week. With a 52-week high of $2.55share, we expect AIKI shares may experience a further near-term gain.
Its been a year since we last reported to you on AIKI. Since then, the company has made significant progress in product development and the current market price seems to be a value. Five recent developments caught our attention and prompted this new report
The company had a cash and equivalents balance of $102 million or approximately $1.15 per share as of March 31st.
CEO Anthony Hayes made three purchases of the company shares over the past 30 days, totaling 30,000 shares at the market price. The purchases increased Mr. Hayes holdings of AIKI shares by 60%.
As per the company 10-Q for Q121, just filed on May 10th, the company has a book value of $1.17 per share.
A key milestone, with testing data publication and technology advancement results, is expected this quarter. There are only a few weeks left in this quarter.
AIKI shares are trading 64% off their February 16th high of $2.55share.
A look at the indicates an RSI 14 value of 43.31 and a share price that has fallen below its 50 DMA of $1.06share and 200 DMA of $.91share. These data can indicate shares that have been oversold.
AIKI is developing its drug pipeline through partnerships with educational institutions, including the University of Texas at Austin, the University of Maryland, Baltimore, and Wake Forest University. The companys oncology therapeutics include prospective treatments for pancreatic cancer, acute myeloid leukemia AML and acute lymphoblastic leukemia ALL.
The Company is also developing a broad-spectrum antiviral platform, in which the lead compounds have activity in cell-based assays against multiple viruses including Influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2, the cause of COVID-19.
AIKI has a book and a cash value position that both exceed the companys market value.
The fact that the AIKI CEO recently bought 30,000 shares at the market with his own funds can be quite telling. What does he know that we dont Everything.
Additional information about the company pipeline is available in this and could be of value in your due diligence process.
Stay tuned for more on AIKI.
Do we disclose any information to outside parties
We do not sell, trade, or otherwise transfer to outside parties your personally identifiable information.
What information do we collect
We collect information from you when you subscribe to our newsletter or fill out a form on one of our social platforms. This includes your email address and or mobile phone number.
When registering on our site, as appropriate, you may be asked to enter your e-mail address and or mobile number.
What do we use your information for
When we collect your email or mobile number it is used for one purpose to send you the information you requested about small cap stocks. Please read our disclaimer carefully before viewing our emails.
Your information, whether public or private, will not be sold, exchanged, transferred, or given to any other company for any reason whatsoever, other than for the express purpose of delivering the information on small cap stocks that you requested.
We send periodic emails
The email address you provide may be used to send you information, respond to inquiries, andor other requests or questions.
How do we protect your information
We implement a variety of security measures to maintain the safety of your personal information when you enter, submit, your email address. We use secure third parties to send email and sms messages to you.
Because we value your privacy we have taken the necessary precautions to be in compliance with the California Online Privacy Protection Act.
This websitenewsletter is a wholly owned subsidiary of Small Cap Specialists LLC, herein referred to as SCS LLC.
Our reportsreleases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our emailblog list as well as any social networking platforms we may use.
PLEASE NOTE WELL SCS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.
Release of Liability Through use of this website viewing or using you agree to hold SCS LLC, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss monetary or otherwise, damage monetary or otherwise, or injury monetary or otherwise that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. SCS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and SCS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead SCS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. SCS LLC is compliant with the Can Spam Act of 2003. SCS LLC does not offer such advice or analysis, and SCS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries and extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions quote may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results.
In preparing this publication, SCS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The owners and operators of this website have been compensated twenty five thousand dollars cash via bank wire for our distributed opinions this week on aiki. The advertisements in this website are believed to be reliable, however, SCS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. SCS LLC is not responsible for any claims made by the companies advertised herein, nor is SCS LLC responsible for any other promotional firm, its program or its structure.
SCS LLC is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission or FINRA.
Copyright 2021 Broad Street Alerts,
Get Every Penny Stock Alert!
OTC Dynamics tracks all penny stock promotions. Become a member today and never miss another penny stock promotion!
OTC Dynamics is not affiliated with the company being promoted or the associated stock promoter.
The information on this page is not a recommendation to buy or sell securities.